Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency


Chronic renal insufficiency is often accompanied by hyperlipidaemia and subsequent coronary heart disease.

Two groups of 15 patients with serum creatinine >2 mg/100 ml and serum cholesterol >250 mg/100 ml were given 3×50 mg magnesium pyridoxal 5-phosphate glutamate (MPPG) or placebo for 12 weeks in a double-blind, randomised study.

Total cholesterol in the MPPG group (282.4 mg·100 ml−1) was lower than in the placebo group (354.3 mg·100 ml−1) after 12 weeks of treatment. Triglycerides in the MPPG group were 265.1 mg·100 ml−1 compared to 361.9 mg·100 ml−1. After 12 weeks on MPPG the LDL/HDL ratio of 3.56 was lower than in the placebo group — 6.83. Side effects in the MPPG group were similar to those in the placebo group. Thus, MPPG was an effective antihyperlipidaemic agent in patients with renal insufficiency.

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.


  1. 1.

    Bagdade JD, Albers JJ (1977) Plasma high-density lipoprotein concentrations in chronic-hemodialysis and renal-transplant patients. N Engl J Med 296: 1436–1439

  2. 2.

    Bagdade JD, Porte D, Bierman EL (1968) Hypertriglyceridemia — a metabolic consequence of chronic renal failure. N Engl J Med 279: 181–185

  3. 3.

    Boberg J, Boberg M, Gross R, Grundy S, Augustin J, Brown V (1977) The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia. Atherosclerosis 27: 499–503

  4. 4.

    Bolzano K, Krempler F, Sandhofer F (1978) Hepatic and extrahepatic triglyceride lipase activity in uraemic patients on chronic haemodialysis. Eur J Clin Invest 8: 289–293

  5. 5.

    Breier Ch, Lisch H-J, Drexel H, Braunsteiner H (1983) Lipoproteine, Apolipoproteine, hepatische Triglyceridlipase und Lecithin-Cholesterin-Acyl-Transferase bei Patienten mit nephrotischem Syndrom. Schweiz Med Wochenschr 113: 909–913

  6. 6.

    Brusis OA, Schmidt A, Upmeyer HJ (1985) Wirksamkeit und Verträglichkeit von Sedalipid bei der Behandlung verschiedener Hyperlipoproteinämien. Fortschr Med 43: 1011–1014

  7. 7.

    Carlson LA, Böttiger LE (1972) Ischemic heart disease in relation to fasting values of plasma triglycerides and cholesterol. Lancet 1: 865

  8. 8.

    Castelli WP, Doyle JT, Gordon T et al (1975) HDL cholesterol levels (HDLC) in coronary heart disease (CHD): a cooperative lipoprotein phenotyping study. Circulation 51 [Suppl 2]: 97

  9. 9.

    Cohen M (1985) Antihyperlipidemic properties ofβ-pyridylcarbinol — a review of preclinical studies. Life Sci 37: 1949–1961

  10. 10.

    Cremer P, Seidel D, Wieland H (1985) Quantitative Lipoproteinelektrophorese: Ihre routinemä\ige Anwendung im Vergleich mit anderen Verfahren zur differenzierten Untersuchung des Fettstoffwechsels. Lab Med 9: 39–51

  11. 11.

    Engel P, Eurich RE (1979) Die Behandlung primärer Hyperlipoproteinämien der IIa, IIb and IV mit Sedalipid. Therapiewoche 29: 5578–5784

  12. 12.

    Franceschini G, Sirtori M, Gianfranceschi G, Frosi T, Montanari G, Sirtori CR (1985) Reversible increase of the Apo CII/Apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Artery 12: 363–381

  13. 13.

    Frederickson DS, Levy RI, Lees RS (1967) Fat transport in lipoproteins — an integrated approach to mechanisms and disorders. N Engl J Med 276: 34–44, 94–103, 215–225, 273–281

  14. 14.

    Gensini GF, Prisco D, Rogasi PG, Matucci M, Serneri GG (1985) Changes in fatty acid composition of the single platelet phospholipids induced by pantethine treatment. Int J Clin Pharm Res 5: 309–318

  15. 15.

    Gentili P, Manzardo S, Riva M (1985) Pharmacological study of a new hypolipidemic drug of prolonged activity, the tetraester of pantethine with 3-(3-pyridinemethoxycarbonyl)proprionic acid. Arzneimittelforsch/Drug Res 35: 1772–1777

  16. 16.

    Gofman JW, Young W, Tandy R (1966) Ischemic heart disease, atherosclerosis and longevity. Circulation 34: 679

  17. 17.

    Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkila EA (1979) Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301: 1073–1076

  18. 18.

    Grützmacher P, Scheuerman E-H, Siede W, Lang PD, Abshagen, Radke HW, Baldamus CA, Schoeppe W (1986) Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: Pharmacokinetics and effects. Klin Wochenschr 64: 910–916

  19. 19.

    Hörl WH, Hörl M, Heidland AA (1982) Fettstoffwechselstörungen bei Nieren-Krankheiten — Pathogenetische Mechanismen. Klin Wochenschr 60: 327–336

  20. 20.

    Hutt V, Wechsler JG, Klör HU, Ditschuneit H (1983) Zur Wirkung vonβ-pyridyl-carbinol auf Lipide und Lipoproteine bei primärer Typ IIa-Hyperlipoproteinämie. Arzneimittelforsch/Drug Res 33: 1682–1684

  21. 21.

    Ibels LS, Stewart JH, Mahony JF, Neall FC, Sheil AGR (1977) Occlusive arterial desease in uraemic and haemodialysis patients and renal transplant recipients. Q J Med 182: 197–214

  22. 22.

    Kannel WB, Castelli WP, Gordon T et al (1971) Serum cholesterol, lipoproteins, and risk of coronary heart disease. The Framingham Study. Ann Intern Med 24: 1

  23. 23.

    Kashyap ML, Srivastava LS, Hynd BA, Brady D, Perisutti G, Glueck CJ, Gartside PS (1980) Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35: 29

  24. 24.

    Lacour B, Roullet J-B, Kreis H, Thevenin M, Drüeke T (1985) Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic real failure with or without haemodialysis, and in renal transplant patients. J Clin Chem Clin Biochem 23: 805–810

  25. 25.

    Lowrie EG, Lazarus JM, Mocelin AJ, Bailey GL, Hampers CL, Wilson RE, Merrill JP (1978) Survival of patients undergoing chronic hemodialysis and renal transplantation. N Engl J Med 288: 863–867

  26. 26.

    Maggi GC, Donati C, Criscuoli G (1982) Pantethine, a physiological lipomodulating agent, in the treatment of hyperlipidemias. Curr Ther Res 32: 380

  27. 27.

    Miller GJ, Miller NE (1975) Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1: 16–19

  28. 28.

    Mordasini R, Frey F, Flury W, Klose G, Greten H (1977) Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med 297: 1362–1366

  29. 29.

    Nagakawa Y, Orimo H, Harasawa M (1985) The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect. Thrombosis Res 40: 543–553

  30. 30.

    Nikkilä EA, Huttunen JK, Ehnholm CE (1977) Effect of clofibrate on postheparin plasma triglyceride lipase activites in patients with hypertriglyceridemia. Metabolism 26: 179–185

  31. 31.

    Panagiotopoulos T, Ketelson UP, Schmidt A, Heuck CC (1986) Long-term effect of magnesium pyridoxal 5-phosphate glutamate in rabbits developing hypercholesterolemia. Arzneimittelforsch/Drug Res 36: 1210–1215

  32. 32.

    Rapoport J, Aviram M, Chaimovitz C, Brook JG (1978) Defective high-density lipoprotein composition in patients on chronic hemodialysis. N Engl J Med 299: 1326–1329

  33. 33.

    Riesen WF, Mordasini R (1984) Hyperlipidemia in renal failure: Phenotypes and pathogenetic mechanisms. Contr Nephrol 41: 312–320

  34. 34.

    Shafrir E, Biale Y (1971) Lipoprotein lipase activity in some rat tissues as influenced by various metabolic situations and by nicotinic acid. In: Gey KF, Carlson LA (eds). Metabolic effects of nicotinic acid and its derivatives. Huber, Bern, pp 515–523

  35. 35.

    Scheffler W, Schwartzkopff W (1980) Frequently used lipid-lowering drugs having no guaranteed effect. Artery 8: 120–127

  36. 36.

    Schlierf G, Oster P (1978) Diagnostik und Therapie der Fettstoffwechselstörungen. Thieme, Stuttgart

  37. 37.

    Shinomiya M, Matsuoka N, Shirai K, Morisaki N, Sasaki N, Murano S, Saito Y, Kumogai A (1980) Effect of pantethine on cholesterol ester metabolism in rat arterial wall. Atherosclerosis 36: 75–80

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kirsten, R., Heintz, B., Nelson, K. et al. Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency. Eur J Clin Pharmacol 34, 133–137 (1988). https://doi.org/10.1007/BF00614549

Download citation

Key words

  • hyperlipidaemia
  • magnesium pyridoxal 5-phosphate glutamate
  • renal insufficiency